Welcome to touchPODCAST where you can listen and learn from our expert faculty, hand-picked from the Touch Medical Media family of independent medical websites. Educating physicians on a fully global scale since 2005! We make positive changes to clinical practice, with the ultimate objective of improving patient and community health. Working alongside leading medical experts, societies and industry, our mission is to provide practical, expert opinions to support best practices for busy Healthcare Professionals globally, by translating published data into easily digestible and timely updates Home of: - touchONCOLOGY - touchENDOCRINOLOGY - touchOPHTHALMOLOGY - touchNEUROLOGY - touchCARDIOLOGY - touchINFECTIOUSDISEASES - touchIMMUNOLOGY - touchRESPIRATORY - touchHAEMATOLOGY - touchDERMATOLOGY This information is intended for use by licensed Healthcare Professionals (HCPs). It should not be considered medical advice, diagnosis, or treatment recommendations.
Episodes
Thursday May 05, 2022
Thursday May 05, 2022
touchMDT for touchONCOLOGY
Listen to an oncology pharmacist and a medical oncologist discuss the rationale for PARP inhibitors for the treatment of advanced prostate cancer.
The multidisciplinary team
- Oncology Pharmacist: Dr Lisa Holle, USA
- Medical Oncologist: Dr Wassim Abida, USA
This touchPODCAST is for HCPs only.
This activity is funded by an unrestricted independent medical education grant from Pfizer. This activity is jointly provided by USF Health and touchIME.
For further information visit our website: https://touchoncologyime.org/mdt-parp-inhibitor-combinations-in-advanced-prostate-cancer/
Comments (0)
To leave or reply to comments, please download free Podbean or
No Comments
To leave or reply to comments,
please download free Podbean App.